Priya P. Chan
No Rating Available
(Learn About Our Rating System)

Priya P. Chan, MD

Languages spoken: English

Clinical Locations

Primary Children's Hospital

Hematology/Oncology
Salt Lake City
801-662-4799
Directions

  • Dr. Chan received her medical degree from the University of Minnesota Medical School, completed her Pediatric Residency at the University of Wisconsin, and her Pediatric Hematology/Oncology Fellowship at the University of Utah. Following fellowship she completed a Pediatric Neuro-Oncology Fellowship at the University of Colorado/Children’s Hospital Colorado.

    Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah in the Division of Pediatric Hematology/Oncology. She is a member of the neuro-oncology team at Primary Children’s Medical Center.

    Dr. Chan’s clinical interests include the care of children and young adults with brain and spine tumors. Dr. Chan’s research interests are focused on the development of early phase clinical trials for children with central nervous system tumors and the long-term care of patients who have survived these cancers.

    Specialties

    Board Certification

    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

  • Dr. Chan received her medical degree from the University of Minnesota Medical School, completed her Pediatric Residency at the University of Wisconsin, and her Pediatric Hematology/Oncology Fellowship at the University of Utah. Following fellowship she completed a Pediatric Neuro-Oncology Fellowship at the University of Colorado/Children’s Hospital Colorado.

    Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah in the Division of Pediatric Hematology/Oncology. She is a member of the neuro-oncology team at Primary Children’s Medical Center.

    Dr. Chan’s clinical interests include the care of children and young adults with brain and spine tumors. Dr. Chan’s research interests are focused on the development of early phase clinical trials for children with central nervous system tumors and the long-term care of patients who have survived these cancers.

    Board Certification and Academic Information

    Academic Departments Pediatrics -Assistant Professor (Clinical)
    Academic Divisions Hematology/Oncology
    Board Certification
    American Board of Pediatrics (Pediatrics)
    American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

    Education history

    Fellowship Pediatric Neuro-Oncology - University of Colorado School of Medicine Fellow
    Fellowship Pediatric Hematology-Oncology - University of Utah School of Medicine Fellow
    Residency Pediatrics, Global Health Track - University of Wisconsin School of Medicine and Public Health Intern/Resident
    Professional Medical Medicine - University of Minnesota Medical School M.D.
    Undergraduate Neuroscience - Johns Hopkins University B.A.

    Selected Publications

    Journal Article

    1. Casey MJ, Chan PPLi Q, Jette CA, Kohler M, Myers BR, Stewart RA (2024). A Simple and Scalable Zebrafish Model of Sonic Hedgehog Medulloblastoma. Cell Rep.
    2. Chan PP, Whipple NC, Ramani B, Solomon DA, Zhou H, Linscott LL, Kestle JRW, Bruggers CS (2023). Patterns of Extraneural Metastases in Children with Ependymoma. J Pediatr Hematol Oncol, 45(2), 272-278.
    3. Chan PP, Sabus A, Hemenway S, Chatfield KC, White CJ, Mirsky DM, Foreman NK, Dahl NA (2023). Thromboemoblic Toxicity Observed with Concurrent Trametiib and Lenalidomide Therapy. Pediatric Blood and Cancer, 70(3), e30190.
    4. Pratt D, Lucas CG, Selvam PP, Abdullaev Z, Ketchum C, Quezado M, Armstrong TS, Gilbert MR, Papanicolau-Sengos A, Raffeld M, Choo-Wossoba H, Chan P, Whipple N, Nasrallah M, Santi M, Ramaswamy V, Giannini C, Ritzman TA, Grundy RG, Burford A, Jones C, Hawkins C, Venneti S, Solomon DA, Adlade K (2022). Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathol, 144(2), 373-376.

    Letter

    1. Shyr DC, Homsombath AA, Chan PP, Boyer MW, Harris AC (2020). Using CD19 chimeric antigen receptor-T cell therapy in a 4-month-old patient with infantile acute lymphoblastic leukemia [Letter to the editor]. Pediatr Blood Cancer, 67(4), e28155. (Read full article)